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A prospective case of postherpetic itch monitored
by quantitative sensory testing for 1 year while
undergoing 8% topical capsaicin treatments
Hjalte H. Andersen, MScMeda, Lars Arendt-Nielsen, PhD, DMSca, Gil Yosipovitch, MDb, Jesper Elberling, PhD, MDc,*
Abstract
Following reactivation of a latent ganglionic varicella zoster virus and skin eruption in the corresponding dermatome(s) ∼20% of
patients develop chronic postherpetic neuralgia. A subset of these patients develop severe and often intractable chronic post-
herpetic itch in the affected area. However, this is rarely studied and little is known about its epidemiology, pathogenesis, and
management. In this case study we followed a patient with moderate to severe chronic postherpetic itch characterized by pure itch
sensation, using standardized quantitative sensory testing and observed a profound loss-of-function for C-fibers, Aδ-fibers, and Aβ-
fibers within the affected area. The testing was conducted before, during, and after 8% topical capsaicin treatments applied in
4 cycles (3 months apart) over the course of∼1 year. During this period the hypoesthesia gradually normalized, but heat hypoalgesia
remained unchanged. The 8% topical capsaicin had a good and long lasting antipruritic effect eventually resulting in complete
resolution of the itch in parallel with partial recovery of initial hypoesthesia, particularly for warmth and cold detection, likely unrelated
to the treatments.
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Introduction
Chronic postherpetic itch (PHI) is a marginally studied sequela to
shingles. After reactivation of a latent ganglionic varicella zoster
virus and skin eruption in the dermatome(s) innervated by a
corresponding sensory ganglion, ∼20% of patients develop
postherpetic neuralgia with advanced age as the major risk
factor[1]. Of these patients an estimated 9%–35% experience
chronic itch without any pain and about half of these experience
itch at an intensity ≥4 on a visual analog scale (VAS0–10 cm)[2,3].
Despite this, PHI has only been sparsely researched and little is
known about its pathogenesis[4,5]. On the basis of evidence
from cases studies, PHI can be as disabling as pain, and is
often intractable[2,4]. Although no controlled trials have been
conducted specifically for PHI, case studies report partial
efficacy of gabapentinoids, topical amitriptyline/ketamine, 8%
topical capsaicin, pulsed radiofrequency treatment, and topical
lidocaine[1,6–9], which is largely in line with treatment for post-
herpetic neuralgia and brachio-radial pruritus. Topically applied
capsaicin causes strong depolarization of intraepidermal tran-
sient receptor potential vanilloid 1 (TRPV1)-positive pruritic and
nociceptive C-fibers of the skin, which results in prolonged,
reversible defunctionalization and deafferentation[10]. The
Qutenza patch (Astellas Pharma Ltd, UK; Now Grünenthal
GmbH, DE) provides topical delivery of 8% capsaicin and is
approved for the treatment of nondiabetic peripheral neuropathic
pain conditions[11]. Here we tested a PHI patient undergoing four
8% topical capsaicin treatment over a year with standardized
quantitative sensory testing and showed, before treatment, a
notable loss-of-function for C-fibers, Aδ-fibers, and Aβ-fibers in
the affected area. Previously, we and others have found sub-
stantial but variable efficacy of 8% topical capsaicin in another
neuropathic itch condition; notalgia paresthetica[12] and a recent
proof-of-concept study showed a powerful antipruritic effect of
8% topical capsaicin on both evoked histaminergic and non-
histaminergic itch[13]. Correspondingly, this PHIpatient had a good
and prolonged antipruritic effect from this treatment, coinciding
with reoccurence of normal sensory function.
A case of chronic postherpetic
A 58-year-old man diagnosed with chronic lymphatic leukemia,
otherwise healthy, developed a severe eruption of herpes zoster in
multiple dermatomes (T1–T2) on the right side of the upper back
(Fig. 1A). In the affected area a vesicular, exuding, and later crust-
forming lesion developed. Treatment of the varicella zoster virus
with Aciclovir (800mg tid) was initiated 1 day after the first signs
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of rash and was effective in halting the outbreak and resolving
most symptoms within 10 days. The skin eruption was not
characterized by pain or paresthesia despite rather severe lesions
(Fig. 1A). After 3–4 weeks when the skin eruption had been
fully reversed, a constant, moderate to severe itch emerged
corresponding to the eruption area. The patient reported being
highly bothered by the itch primarily in the evenings and in the
morning, while the intensity diminished somewhat during the
day. Moreover, the patient reported an average itch intensity of 6
on a VAS0–10 (0: “no itch,” 10: “worst imaginable itch”). Initially
Figure 1. A, Active virus eruption. B, demarcation of the area of itch (1), application of an appropriately sized 8% capsaicin patch (2), axon-reflex-flare resulting from
the capsaicin treatment immediately after patch removal (3). C, Sensory profile as assessed by quantitative sensory testing (notice the pronounced hypoesthesia of
several parameters, which recovered during the 1 year and the contrasting stabile heat hypoalgesia). D, Demarcation of the area of itch (1) and fourth treatment (2)
(see the diminished size of the area). CDT indicates cold detection threshold; HPT, heat pain threshold; MDT, mechanical detection threshold; MPT, mechanical
pain threshold; WDT, warmth detection threshold.
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the patient did not experience significant touch-evoked itch
(alloknesis) to, for example, wool fabrics, but this had developed
at the second consultation. A treatment course with Gabapentin
(300mg bid) was ineffective in substantially reliving the itch.
After 7 months with moderate to severe itch the patient was
referred to our department and offered off-label treatment with
8% topical capsaicin. The patient consented to the 8% topical
capsaicin treatment and the sensory testing as well as to the
anonymized data being used for a case report. During the 1-hour
capsaicin administration the patient experienced significant acute
pain necessitating the use of Tramadol (50mg, oral) during
the following treatments, which made the treatment tolerable.
The patient underwent 4 treatment cycles; 1 per 3 months (over
∼1 year), of which the efficacy and temporal effect of the treat-
ment gradually increased, that is, after the first treatment the
patient reported 2 weeks of complete itch relief, whereafter the
itch slowly remerged over the course of 2–3 months and
approximated the initial level when next treatment was admi-
nistered. The treatment effect increased progressively during the 4
cycles, so that the patient was free of itch for longer periods and
that the reemergence of itch was less complete. The patient did
not receive any regular treatment for chronic lymphatic leukemia
or other prescriptionmedications during the 8% topical capsaicin
treatment period. Before the fourth capsaicin treatment the
patient reported the average itch to be around 10%of the severity
level reported at the initial treatment, that is, <1 (VAS0–10).
Furthermore he stated following the third treatment he was
almost unbothered by itch except during exercise or when
wearing certain synthetic fabrics. Approximately 9 months after
the fourth treatment the last follow-up was performed and the
patient reported being almost entirely free of itch, expect from
mild itch occurring during strenuous exercise (spinning classes).
Methods: quantitative sensory testing
Immediately before capsaicin treatment no.: 1, 3, and 4, selected
quantitative sensory testing (QST) parameters were assessed
following the German Research Network on Neuropathic pain
(DFNS) standardized protocol[14]. This was done to get a repre-
sentative sensory profile before treatment initiation and to assess
sensory implications of the repeated capsaicin administration.
The testing always included both the affected and unaffected
contralateral side (used as control) and the sensory parameters
assessed were mechanical detection threshold (MDT, touch Aβ-
fibers), mechanical pain threshold (MPT, Aδ-fibers), cold detec-
tion threshold (CDT, cold Aδ-fibers), warmth detection threshold
(WDT, warmth C-fibers), and heat pain threshold (HPT, heat
C-fibers). MDT was determined with a set of 20 calibrated Von
Frey filaments (North Coast Medical, CA) with exerted forces
ranging from 0.078mN to 2.9 N was applied as ascending/des-
cending series of stimuli. The patient was asked to report upon
any sensation from the area. The MPT was evaluated using a set
of 7 weight-calibrated pinprick stimulators (MRC Systems,
Germany) with weights from 8 to 512mN. The patient reported
when a perception of “sharpness” or “pricking pain” was sensed
during ascending/descending series of stimuli. CDT, WDT, and
HPTwere performed using aMedoc Q-sense (Medoc Ltd, Ramat
Yishay, Israel) equipped with a 3× 3 cm thermal probe. Ramping
stimuli of 1°C/s were delivered from an adaptation temperature
of 32°C until the patient identified the relevant threshold (first
perception of cold, warmth or heat-induced pain) by pressing a
button. Thresholds were assessed by the method of limits in tri-
plicates (thermal) and quintuplicates (mechanical), and the dif-
ferences expressed as z-scores ([z= (χ-μ)/σ], hereby conveying the
n difference of SD between the affected and nonaffected side).
QST parameters were selected based on (1) being relevant to
probing of superficial cutaneous fibres, (2) having access to the
relevant equipment, and (3) being able to conduct the testing in
30–35 minutes. The sensory testing was always performed by the
same investigator in a quiet examination room. The area of
alloknesis was assessed by gentle radial strokes with a finger from
outside and toward the suspect itching area.
Results: quantitative sensory testing
Immediately before each treatment the itch area was defined by
lightly stroking the skin with the fingertips from well outside the
relevant area and toward the center. The resultant area was
marked, quantified, and treated (Fig. 1B, 1–3). Before the first
capsaicin application the QST showed considerable tactile and
thermal hypoesthesia as well as thermal hypoalgesia in the
affected region compared with the contralateral side (Fig. 1D).
WDT, CDT, HPT, and MDT were all reduced by > 2 SDs in the
herpes zoster eruption site. The only sensory modality relatively
unaffected was MPT (ie, never differing >2 SDs) but it was still
consistently higher in the site of the herpes zoster flare-up (aver-
age, 174.9 ± 111.2 mN) than in the contralateral site (average
100.8 ± 49.4 mN). Before the third and fourth capsaicin treat-
ments normalization of hypoesthesia, but not hypoalgesia, was
observed across the assessed parameters, in particular for CDT as
well as MDT. Moreover, the WDT also showed signs of nor-
malization, but never recovered to <2 SDs of the unaffected
control area. Lastly, during the 4 treatment cycles the spatial
extend of the itch/alloknesis area greatly diminished from ∼280
cm2, to 200 cm2, to 140 cm2, and to 65 cm2 (Fig. 1D, 1–2) before
the last treatment. The patient himself spontaneously reported
experiencing a decrease in the area of itch at the fourth con-
sultation before the area assessment.
Discussion
We here present the first long-term QST-based monitoring of a
patient with PHI and report the observation of considerable
sensory loss in the affected area with a tendency toward gradual
recovery over the course of 1 year. Achieving satisfactory relief in
patients suffering from neuropathic itch such as in PHI is a clin-
ical challenge (as is the case for postherpetic pain)[1,4].
Etiologically, PHI follows a varicella zoster virus eruption but
the mechanism(s) behind the development of chronic itch is cur-
rently unknown and in particular, it is unclear why patients
develop highly diverse sensory symptomatology[15,16]. In this
patient considerable sensory loss-of-function in the lesional skin
area was evident for several QST parameters indicating defunc-
tionalization of several cutaneous nerve fiber classes (Fig. 1C). In
a previous case of severe postherpetic pruritus, hypoesthesia and
hypoalgesia was also reported[7]. Using contralateral control
QST data is generally associated with higher sensitivity than
applying normative data for comparison and thus applied in this
report[17]. However, it should be noted that while the recorded
hypoesthesia to thermal and mechanical stimuli was pronounced
also in comparison to a normative dataset, the heat hypoalgesia
was to a large extent driven by low (but still within normal range)
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HPT in the unaffected control area[17]. In the present study the
hypoesthesia but not the hypoalgesia in the affected skin area
gradually reversed during the 1 year that the patient was followed
and this decline corresponded to the reduction of itch. The tested
PHI patient appear to fit the “sensory-loss phenotype” frequently
described in large QST studies in neuropathic pain patients. It is
seemingly paradoxical that considerable multimodal loss of
sensory function in a skin area can produce insatiable sponta-
neous and touch-evoked itch. A conceivable mechanism via
which this could occur is a loss of afferent sensibility to tactile and
thermal stimuli in the area caused by the varicella zoster eruption
leading to spinal disinhibition of itch transmission from remain-
ing pruriceptive fibers. A similar pathoetiology has previously
been suggested and seems to be consistent with the fact that
pruriception is highly gated at the spinal level by both nociceptive
and mechanoreceptive input through recently discovered distinct
populations of itch-specific inhibitory interneurons[4,18]. Another
potential mechanism that could be involved is selective peripheral
sensitization of pruriceptive nociceptors perhaps prompted sec-
ondarily to skin damage and inflammatory mediators associated
with the virus eruption. However, this mechanism alone can
hardly explain the chronicity of the itch and the sensory loss
occurring in the area. Notably, HPT, which can be increased by
capsaicin treatment, did not show signs of normalization during
the repeated capsaicin treatments. This is unlikely to be related to
the capsaicin treatments however, since previous studies have not
shown any prolonged increase in HPT in healthy controls[19] or
neuropathic pain patients following an 8% capsaicin treatment.
Morever, WDT which is in fact profoundly increased by 8%
capsaicin did normalize substantially in our patient[20]. Similarly,
the slow but gradual normalization of thermal and mechanical
detection thresholds is likely associated with natural recovery
rather than the treatment since another study found no effect on
MDT alongside prolonged warmth hypoesthesia following a
single 8% capsaicin treatment[20].
Itch and pain are highly entwined sensory modalities and it has
previously been described that while certain analgesics have a
favorable effect on itch (eg, κ-opioid-agonists, lidocaine, and
gabapentinoids) others may evoke and exacerbate itch (eg, μ-
opioids)[21]. In the present case, 4 cycles of topical 8% capsaicin
effectively alleviated chronic PHI and was well tolerated by the
patient when tramadol was applied before the capsaicin treat-
ments. Previous case studies of neuropathic itch have found a
similar effect of 8% topical capsaicin and often noted significant
improvements following a single treatment only.
As the spatial acuity of itch is poor, probing the area of
touch-evoked itch manually or with a von Frey filament (as
previously described[12] is a useful way to determine the exact
area of patch application in patients without visible skin man-
ifestations). A previous brief review describes practical aspects
of conducting 8% capsaicin patch treatments for neuropathic
itch conditions[22].
Further studies using both QSTs designed for general soma-
tosensory assessment (eg, the DFNSmethodology) as well as QST
tailored specifically for chronic itch patients, for example, gain/
loss of pruriceptive function, are needed. Although significant
sensory loss have previously been noted in a patient with PHI it is
unclear whether the presently observed aberrations are typical for
neuropathic itch conditions as only case studies have been pub-
lished. In conclusion, there seem to be no hindrances to applying
8% topical capsaicin with intractable PHI as an indication, but
future RCTs are needed to adequately elucidate its efficacy and
safety profile in this patient group.
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